ARMATA PHARMACEUTICALS INC (ARMP) — insider trading
Health Care · Nyse Mkt Llc
ARMATA PHARMACEUTICALS INC (ARMP) has 11 reported SEC Form 4 insider transactions in our data (latest 2026-04-24).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-04-24 | Gilmer Daniel B. | Director | Grant / award / vesting (derivative) | 51,280 | $0.00 | $0 | Form 4 |
| 2026-03-14 | Birx Deborah | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 4,919 | $10.54 | $51.8K | Form 4 |
| 2026-03-14 | Kyme Pierre | Officer (Chief Business Officer) | Shares withheld for taxes / exercise cost | 1,030 | $10.54 | $10.9K | Form 4 |
| 2026-03-09 | Schlesinger Sarah J. | Director | Grant / award / vesting (derivative) | 25,640 | $0.00 | $0 | Form 4 |
| 2026-03-09 | Birx Deborah | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 421,226 | $0.00 | $0 | Form 4 |
| 2026-03-09 | Odysseas Kostas D | Director | Grant / award / vesting (derivative) | 25,640 | $0.00 | $0 | Form 4 |
| 2026-03-09 | Peterson Todd C. | Director | Grant / award / vesting (derivative) | 25,640 | $0.00 | $0 | Form 4 |
| 2026-03-09 | PATTI JOSEPH M | Director | Grant / award / vesting (derivative) | 25,640 | $0.00 | $0 | Form 4 |
| 2026-03-09 | House David Duane | Officer (SVP, Finance, and PFO) | Grant / award / vesting (derivative) | 109,885 | $0.00 | $0 | Form 4 |
| 2026-03-09 | Kyme Pierre | Officer (Chief Business Officer) | Grant / award / vesting (derivative) | 183,142 | $0.00 | $0 | Form 4 |
| 2026-03-09 | Kramer Robin | Director | Grant / award / vesting (derivative) | 25,640 | $0.00 | $0 | Form 4 |
Ask the chat about ARMP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARMATA PHARMACEUTICALS INC (ARMP).
Last updated 2026-04-24 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.